Back to Acceleration Radar
CHEChemed Corp
Health Care · Medical/Nursing Services · Mid
$512.98−1.38%
As of 23 Oct 2026Mkt cap $6.8B
Stage 13
WAIT
Fundamentals
47.7/75
Technical
6.8/15
Independent
54.5/90
GCAE viewelevated earnings event risk blocks an independent BUY decision
Price
- 1M
- +3.5%
- 3M
- +0.7%
- 6M
- +21.8%
- 1Y
- +16.8%
Financials & valuation
Cached filing evidence · as of 2026-10-02
Valuation
- P/E
- 25.8xHist median 24.9x
- Forward P/E
- —No validated forward-estimate source
- Price / FCF
- 22.9x
- FCF yield
- 4.4%
Quality
- ROIC
- 23.7%
- Operating margin
- 15.0%
- FCF margin
- 12.9%
- Current ratio
- 1.1x
Growth
- Revenue growth
- +4.1%Latest FY YoY
- Revenue CAGR
- +4.3%
- EPS CAGR
- +2.1%
- FCF CAGR
- +6.8%
Capital
- Share-count trend
- −2.5%3Y annualised
- Net debt
- $69M0.2x OCF
Annual trend
- CAGR 2021–2025
- +4.3%
- Latest · 2025
- $3B
- YoY
- +4.1%
GCAE Research
- Quality Research
- NOT FLAGGED
- Acceleration Radar
- FUNDAMENTAL GATE FAIL
- THE ONE
- NOT FLAGGED
- Final / Opportunity
- NOT FLAGGED
Key takeaway
elevated earnings event risk blocks an independent BUY decision
Unresolved question
No reliable unresolved question is available from the current committed evidence.
Watch next
- Next earnings · 2026-10-27
More details & evidence
Production decision
- Stage 13
- WAIT
- Technical state
- approaching-support
- Rotation
- tailwind
- Evidence
- fresh
Presentation freshness
- Stage 11 market
- 2026-10-23 · Massive
- Financial cache
- 2026-10-02
- Quality Research
- NOT FLAGGED
- THE ONE
- NOT FLAGGED
Authority
- Company page
- Presentation only
- Scores
- Frozen GCAE production outputs
- Research
- Research-only lanes; no score override
- Private portfolio
- Not loaded